Clinical Trial Update: Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating MDX-010 (ipilimumab) alone and in combination with dacarbazine for metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: COMPLETED